Skip to Content

Prialt Approval History

FDA Approved: Yes (First approved December 28, 2004)
Brand name: Prialt
Generic name: ziconotide
Dosage form: Intrathecal Infusion
Company: Elan Corporation, plc
Treatment for: Pain

Prialt (ziconotide) is a non-opioid intrathecal (IT) therapy indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine.

Development History and FDA Approval Process for Prialt

DateArticle
Dec 28, 2004Approval Prialt Elan Corporation, plc - Treatment for Severe Chronic Pain
Jun 28, 2004Elan Files Amendment to New Drug Application for Prialt for Severe Chronic Pain Based on Additional Efficacy and Safety Data

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide